Parsippany. New Jersey. Ascend Laboratories LLC. is voluntarily recalling Dabigatran Etcxilate Capsules. USP 75 mg and 150 mg to the consumer/user level due to the presence of a nitrosamine. N-nitroso-dabigatran, above the established Acceptable Daily Intake (ADI) level. To date, Ascend Laboratorie
“Health systems were underfunded and poorly prepared for what was to come,” – @DirOPSPAHO looking back at the regional context before the COVID-19 pandemic.
